Lifepoint Multispeciality Hospital

Running trials

• Not yet recruiting

  A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

  NCT07881432· Phase 3· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Phase 2· Source

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Schizophrenia

  NCT07410507· Phase 2· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  NCT07321886· Phase 3· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

  NCT07286175· Phase 2· Source

• Recruiting

  A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

  NCT07219173· Phase 2· Source

• Recruiting

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  NCT06119581· Phase 3· Source

• Active, not recruiting

  A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  NCT05869903· Phase 3· Source

• Active, not recruiting

  A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

  NCT04975308· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity2 recruiting
• Type 2 diabetes2 recruiting
• Asthma1 recruiting
• Bipolar disorder1 recruiting
• COPD1 recruiting
• Lung cancer1 recruiting
• Schizophrenia1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

  NCT05929066· Phase 3· Source